BioSpace News Archive

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today received notice regarding the U.S. Patent Office (USPTO) Patent Trial and Appeal Board (PTAB) decision to institute trial on the Inter Partes review (“IPR”) filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036.

Singapore-based diagnostics developer and medical laboratory operator, INEX Innovate has contributed an undisclosed sum to leading Hong Kong university – The Chinese University of Hong Kong (CUHK), to collaborate and further research in the field of maternal fetal medicine.

The Barbara Ann Karmanos Cancer Hospital welcomes Brian Gamble into a new role as President.

Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO), today announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the development of a novel cytokine derivative therapeutic for the treatment of cancer.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will present at the Canaccord Genuity 42nd Annual Global Growth Conference on August 10, 2022 beginning at 8:00 AM ET.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), today announced that members of the management team will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference at the InterContinental Boston Hotel.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced that the company will participate in the following upcoming conferences.

Summit Therapeutics Inc. announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer & President, effective immediately.

Applied Genetic Technologies Corporation announced that the U.S. Food and Drug Administration provided favorable feedback on the Current Good Manufacturing Practice design of AGTC’s manufacturing facility.

Sensus Healthcare, Inc. announces that management will hold a conference call on Thursday, August 4, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2022.